{
    "2019-06-09": [
        [
            {
                "time": "2022-06-15",
                "original_text": "Trulicity® (dulaglutide) significantly reduced major cardiovascular events for broad range of people with type 2 diabetes",
                "features": {
                    "keywords": [
                        "Trulicity",
                        "dulaglutide",
                        "reduced",
                        "cardiovascular",
                        "events",
                        "type 2 diabetes"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2022-06-15",
                "original_text": "Lilly's ultra rapid lispro provided similar A1C reductions compared to Humalog® (insulin lispro), with superior post-meal blood glucose reductions",
                "features": {
                    "keywords": [
                        "Lilly",
                        "ultra rapid lispro",
                        "A1C",
                        "Humalog",
                        "insulin lispro",
                        "post-meal",
                        "blood glucose"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2022-06-15",
                "original_text": "Lilly's tirzepatide demonstrates benefits in data presented at the American Diabetes Association's® 79ᵗʰ Scientific Sessions®",
                "features": {
                    "keywords": [
                        "Lilly",
                        "tirzepatide",
                        "benefits",
                        "American Diabetes Association",
                        "Scientific Sessions"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}